RJA
AGN

Raymond James & Associates’s Allergan plc AGN Stock Holding History

Raymond James & Associates’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-276,970
Closed -$49.1M – 3726
2020
Q1 		$49.1M Sell
276,970
-260,919
-49% -$49.1M 0.08% 215
2019
Q4 		$103M Sell
537,889
-41,722
-7% -$7.53M 0.13% 137
2019
Q3 		$97.5M Sell
579,611
-107,068
-16% -$17.4M 0.14% 139
2019
Q2 		$115M Sell
686,679
-58,261
-8% -$8.07M 0.17% 115
2019
Q1 		$109M Buy
744,940
+97,632
+15% +$14.2M 0.17% 114
2018
Q4 		$86.5M Sell
647,308
-126,099
-16% -$20.7M 0.15% 117
2018
Q3 		$147M Buy
773,407
+105,115
+16% +$19.3M 0.23% 86
2018
Q2 		$111M Buy
668,292
+26,578
+4% +$4.27M 0.19% 107
2018
Q1 		$108M Buy
641,714
+109,118
+20% +$18.3M 0.19% 102
2017
Q4 		$87.1M Sell
532,596
-50,816
-9% -$9.12M 0.16% 122
2017
Q3 		$120M Sell
583,412
-1,214
-0.2% -$282K 0.24% 85
2017
Q2 		$142M Buy
584,626
+25,778
+5% +$6.06M 0.31% 58
2017
Q1 		$134M Buy
558,848
+82,091
+17% +$19.1M 0.31% 56
2016
Q4 		$100M Buy
476,757
+90,524
+23% +$18.8M 0.26% 77
2016
Q3 		$89M Buy
386,233
+28,153
+8% +$6.88M 0.24% 85
2016
Q2 		$82.7M Buy
358,080
+58,982
+20% +$13.6M 0.26% 75
2016
Q1 		$80.2M Sell
299,098
-47,307
-14% -$13.5M 0.27% 71
2015
Q4 		$108M Buy
+346,405
New +$103M 0.39% 43
2015
Q2 		– Sell
-255,311
Closed -$76M – 2474
2015
Q1 		$76M Buy
255,311
+35,786
+16% +$10.2M 0.33% 51
2014
Q4 		$56.5M Buy
219,525
+69,632
+46% +$17.4M 0.28% 69
2014
Q3 		$36.2M Buy
149,893
+103,434
+223% +$23.1M 0.21% 86
2014
Q2 		$10.4M Buy
46,459
+9,243
+25% +$1.91M 0.06% 344
2014
Q1 		$7.66M Sell
37,216
-1,120
-3% -$222K 0.05% 410
2013
Q4 		$6.44M Buy
38,336
+3,315
+9% +$518K 0.05% 433
2013
Q3 		$5.04M Sell
35,021
-17,060
-33% -$2.27M 0.04% 468
2013
Q2 		$6.57M Buy
+52,081
New +$5.9M 0.06% 349

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Raymond James & Associates's AGN Position: Q2 2020 in Review

Raymond James & Associates sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 276,970 shares — an estimated $49.1M sold.

Raymond James & Associates first reported a position in AGN in Q2 2013 and held it in 26 quarters. The position peaked at $147M in Q3 2018. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • Raymond James & Associates reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • Raymond James & Associates sold 276,970 Allergan plc shares in Q2 2020, an estimated $49.1M.
  • Raymond James & Associates first reported a position in Allergan plc in Q2 2013 and held it in 26 quarters.
  • Raymond James & Associates's Allergan plc position peaked at $147M in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on Raymond James & Associates's 13F filing for Q2 2020, filed 28 Jul 2020.